Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers

Abstract Background Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended p...

Full description

Bibliographic Details
Main Authors: Hye Sook Chon, Sokbom Kang, Jae K. Lee, Sachin M. Apte, Mian M. Shahzad, Irene Williams-Elson, Robert M. Wenham
Format: Article
Language:English
Published: BMC 2017-06-01
Series:BMC Cancer
Subjects:
Oral ridaforolimus
Phase 1 trial
Paclitaxel and carboplatin combination
Solid tumors
Online Access:http://link.springer.com/article/10.1186/s12885-017-3394-2

Internet

http://link.springer.com/article/10.1186/s12885-017-3394-2

Similar Items